MS Phase 3 Study Laquinimod BRAVO Report for Patients Like You

Filter by:

All
Start typing to see suggestions

patients

Home > Community Treatment Reports and Side Effects > MS Phase 3 Study Laquinimod BRAVO Treatment Report

You appear to have JavaScript disabled in your browser. PatientsLikeMe relies on JavaScript and Cookies to deliver the best possible experience to you. How do I enable JavaScript?

What is MS Phase 3 Study Laquinimod BRAVO?

NCT00605215 is a multinational, randomized, parallel-group study performed in subjects with RRMS to assess the efficacy, safety and tolerability of laquinimod over placebo in a double-blind design and a reference arm of interferon β-1a. Other study IDs include: MS-LAQ-302, EUDRACT 2007-005450-23.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose	# of patients	# of patients with evaluations Efficacy	Major	Moderate	Slight	None	Can’t tell
Participate in clinical trial	1	0

See 1 patient currently using MS Phase 3 Study Laquinimod BRAVO

Mouse over the table for more information

Reported Schedules

	1 mg daily
	1

Report created on May 27, 2012.